Aeva Technologies, Inc. (AEVA): Nasdaq/NYSE listing notice — Aeva receives NYSE non-compliance notice for average stock price below $1.00

Aeva Technologies, Inc.

Notice dated Sept 21, 2023: average closing price of common stock below $1.00 over 30 consecutive trading days.
Company has a six-month cure period; can regain compliance if closing price ≥ $1.00 at month-end and 30-day average ≥ $1.00.
No immediate impact on listing; stock remains traded on NYSE during cure period.
Company intends to consider available alternatives to cure the deficiency.
Warrants (AEVA.WS) also listed on NYSE; notice only directly addresses common stock.

item 3.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Aeva Technologies, Inc. received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).

Exchange: nyse
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 802.01C

Exact text from the filing

September 21, 2023, Aeva Technologies, Inc. (the “Company”), received a written notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that it was not in compliance with the continued listing standard set forth in Section 802.01C of the NYSE’s Listed Company Manual (“Section 802.01C”), as the average closing price of the Company’s common stock (the “Common Stock”) was less than $1.00 per share over a consecutive 30 trading-day period. The Notice has no immediate impact on the listing of the Company’s common stock, which will remain listed and traded on the NYSE during the cure per

View on SEC.gov

Browse all listing & compliance notices →

Aeva Technologies, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-049462

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.